APOA1 and metabolic dysfunction-associated steatotic liver disease: In the “NAFLD-Biopsy” cohort, ApoA1 levels were already significantly decreased (−0.30 g/L) in women with T2DM compared with non-T2DM patients from the age of 30 years (Figure 5), whatever the confounders (Supplementary Figures S2–S4).